GH: SEC Form 10-Q filed by Guardant Health Inc.
Q3 2026 10-Q filed; deferred revenue fell to $45.1M from $59.7M at Dec 2025, with 135.3M shares outstanding.
What this filing says
The filing is Guardant Health's quarterly report for the period ended September 30, 2026. It shows deferred revenue fell to $45.1 million from $59.7 million, and the excerpt describes a nine-month net loss of $287.8 million in the prior-year period, so shareholders should review the full statements for the current results.
Key figures
- Deferred revenue at Sept. 30, 2026
- $45.1 million
- Deferred revenue at Dec. 31, 2025
- $59.7 million
- Long-term deferred revenue at Sept. 30, 2026
- $7.0 million
- Shares outstanding as of Oct. 30, 2026
- 135,285,975 shares
- Nine-month net loss (2025 comparison)
- $287.8 million
- Cash used in operations (2025 comparison)
- $158.4 million
Positive for shareholders
- Deferred revenue declined, so some previously billed services have been recognized as revenue.
Negative for shareholders
- Revenue on oncology and screening tests is estimated when tests are provided and may later be reversed if cash collected differs, adding uncertainty to reported revenue.
- Possible coding changes could reduce, hold or eliminate payments for certain test uses.
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- Deferred revenue:
- Cash customers have paid in advance for services the company has not yet performed, recorded as a liability until the work is done.
- Reconciliation adjustments:
- Non-cash items such as stock compensation and depreciation that are added back to net loss to arrive at cash used in operations.
- Variable consideration:
- Payments that may rise or fall, so revenue is estimated at the time of sale and adjusted later once the actual amount is known.
FAQ
How much did Guardant Health's deferred revenue change in this filing?
Deferred revenue was $45.1 million at September 30, 2026, down from $59.7 million at December 31, 2025, with $7.0 million classified as long-term.
Why could Guardant Health's reported revenue change later?
The company records estimated revenue when a test is provided and adjusts it if the cash it later receives differs, and the filing notes this variability could increase the risk of future revenue reversals.
Historical context for GH
Across the 25 sessions after earlier GH headlines, the stock closed higher 16 times and lower 9 times, with a median move of 3.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | GH | SPY |
|---|---|---|---|
| Nov 5, 2026 | TwinStrand Biosciences Announces USPTO Confirmation of Patentability of Core Duplex Sequencing Patent | -9.0% | -4.4% |
| Nov 4, 2026 | Kevin Sayer Joins Guardant Health Board of Directors | -3.7% | +1.7% |
| Nov 3, 2026 | Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test | +2.5% | +0.3% |
| Oct 29, 2026 | Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians | +1.5% | -0.4% |
| Oct 23, 2026 | Roth Capital initiated coverage on Guardant Health with a new price target | +3.8% | -0.5% |
| Oct 20, 2026 | Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026 | +3.0% | +0.3% |
Keep researching GH
- GH financial statementsRevenue, profit, cash flow and balance sheet from Guardant Health Inc.'s SEC filings.
- What is Form 10-Q?The quarterly report US public companies file with the SEC for each of the first three fiscal quarters, with unaudited financial statements and MD&A.
- Form 10-K vs 10-QThe difference between a 10-K and a 10-Q: what each report contains, filing deadlines by company size, audited vs reviewed financials, and which sections to read first.
- GH insider tradesEvery buy and sale reported by Guardant Health Inc. officers, directors and large holders.
- GH earnings historyPast Guardant Health Inc. earnings releases, newest first.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical Specialities
- Listed since
- 2018
Follow GH and get a push notification the moment its next story breaks.